Every few years, a new substance slips into the mainstream before most employers have had time to understand what it is, how it is being sold, or what kind of risk it may create on the job. Right now, that substance is 7-hydroxymitragynine (7‑OH)—a potent kratom-related compound that critics and headlines have started calling “gas station heroin.”

That nickname is provocative, but the underlying issue is real. For employers in DOT-regulated and other safety-sensitive industries, 7‑OH raises urgent questions about workplace drug testing, impairment, policy language, and DOT compliance. It is widely available, poorly understood by the public, and increasingly relevant to companies trying to keep workplaces safe.

At its simplest, 7‑OH is an alkaloid linked to the kratom plant, Mitragyna speciosa. But the version attracting attention today is not the same thing many people picture when they hear the word kratom. Traditional kratom products have typically been associated with raw leaf or minimally processed material. By contrast, newer concentrated kratom products and high-potency alkaloid extracts may contain far stronger levels of 7‑OH.

In the natural leaf, 7‑OH appears only in very small amounts. What has changed is the marketplace: some manufacturers are now producing products with concentrated or synthetic levels of 7‑OH, turning what was once a minor component into the main attraction. [Study]

That distinction matters. Federal health authorities have warned that some products sold under the kratom label are, in practice, chemically different from the natural plant and may present a very different level of risk. [Study]

The phrase “gas station heroin” did not catch on by accident. It reflects two realities that keep showing up in reporting and regulatory warnings: where these products are sold, and how powerful they may be.

1. Widely Available in Retail Environments

7‑OH products are commonly sold:

• In gas stations
• Vape and smoke shops
• Online marketplaces

They are often sold as gummies, tablets, shots, and drink mixes in places consumers do not typically associate with high-risk substances—and not always with clear labeling. [FDA]

2. Opioid-Like Effects and Potency

The other reason for the nickname is pharmacology. 7‑OH interacts with the brain’s μ-opioid receptors, which is why toxicologists and regulators are treating it as more than just another herbal trend. [UVA]

Research and regulatory analysis indicate that:

• It can be more potent than morphine [FDA]
• It binds significantly more strongly than mitragynine [UVA]
• It carries risks of respiratory depression, dependence, and overdose [ADAI]

For employers, the bigger story is not simply kratom itself. It is the way the market has shifted toward concentrated kratom products, synthetic or semi-synthetic 7‑OH, and other emerging drug trends that blur the line between supplement, intoxicant, and high-risk substance.

Historically:

• Kratom = low-level psychoactive plant material
• 7‑OH = minor byproduct

Today:

• Products are increasingly engineered to contain high concentrations of 7‑OH
• Some commercial samples show dramatically elevated levels compared to natural kratom [CFSRE]

In practical terms, that means employers are no longer looking at a simple plant-based product. They are increasingly confronting a novel psychoactive substance (NPS) market built around potency, convenience, and inconsistent disclosure.

That shift helps explain why public health agencies, toxicologists, and regulators are paying closer attention. What might once have been dismissed as a fringe product is now being treated as an opioid-like substance with growing significance as a public health concern.

FDA Action

The FDA has:

• Warned about serious safety and abuse risks
• Recommended scheduling certain 7‑OH products
• Highlighted their availability in unregulated retail environments [FDA]

CDC Data Trends

Public health surveillance shows:

• A sharp increase in kratom-related poison center calls
• Increased exposure to high-potency and multi-substance products [CDC]

Toxicology Warnings

Experts describe 7‑OH as:

• A “high-risk supplement marketed as kratom”
• A substance with opioid-level potency and overdose risk [ACMT]

For employers in transportation, construction, logistics, and other safety-sensitive industries, the implications are hard to ignore. 7‑OH touches multiple pressure points at once: workplace drug testing, supervisor awareness, drug-free workplace policies, and DOT compliance obligations.

1. Impairment Risk

7‑OH can cause:

• Sedation
• Slowed reaction time
• Euphoria
• Respiratory depression

For DOT-regulated operations and other employers with safety-sensitive employees, those effects are not abstract health concerns. They translate directly into workplace safety risk.

👉 Learn how to strengthen your workplace drug testing program with our
Drug Testing Services

2. Detection Challenges

Unlike traditional opioids:

• 7‑OH is not always included in standard drug panels
• It may be missed without specialized or expanded testing

That creates a difficult gap for employers who rely on routine testing programs. Depending on the role, the policy, and the level of risk involved, an expanded drug testing panel or a broader strategy for emerging substances may deserve serious consideration.

👉 Explore training and compliance support through our
Supervisor Training Course

3. Legal Does Not Mean Safe

Many 7‑OH products:

• Are sold legally or semi-legally
• Lack FDA approval
• Have no standardized labeling or dosing

That is an important distinction for employers. A product can still be sold in the open, marketed as legal, and yet pose serious safety concerns. The FDA has made clear that these products are not approved for use and may pose serious health risks. [FDA]

4. Policy and Compliance Gaps

Because 7‑OH exists in a regulatory gray area, many employer policies:

• Do not explicitly address it
• Fail to cover emerging or synthetic analog substances

👉 Keep your business protected with our
DOT Compliance Program

5. Misleading Marketing and Labeling

Products are often:

• Marketed as “natural” or “kratom”
• Appealing in forms like gummies or drink shots
• Missing accurate potency disclosures

This increases the risk of unintentional use and misuse, especially among younger workers.

None of this means employers need to panic. It does mean they need to get ahead of the issue. Companies that respond well to emerging drug trends are usually the ones that strengthen education, tighten policy language, and take a more thoughtful approach to workplace drug testing.

✅ Educate Supervisors and Employees

Provide training on:

• Emerging drug trends
• Signs of impairment
• Risks of “legal” substances

👉 Start with our
Supervisor Training Course

✅ Review Drug Testing Programs

Work with a provider that:

• Tracks emerging drug trends
• Offers expanded or customized panels
• Supports compliance with DOT regulations

✅ Update Drug-Free Workplace Policies

Ensure policies:

• Include synthetic and emerging substances
• Clarify that legality ≠ acceptable use
• Address safety-sensitive responsibilities

✅ Stay Current on Regulations

With ongoing FDA and DEA action, employers must stay informed and ready to adapt.

7‑OH marks a new chapter in the substance landscape: one in which high-potency, opioid-like compounds are being sold outside the channels many employers instinctively watch most closely.

For employers, especially in DOT-regulated industries, this reinforces a critical truth:

Substances don’t have to be illegal to create serious workplace risk.

For employers, the takeaway is straightforward. By strengthening workplace drug testing programs, updating policies, and staying alert to emerging drug trends, organizations can better protect their workforce, support DOT compliance, and reduce risk in safety-sensitive environments.